News | July 24, 2025
Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
Changhua site meets international regulatory standards for global medical applications
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The company will provide the necessary response to USFDA within stipulated 15 days
25 women students to receive internship, training, and mentorship in Life Sciences segment
Subscribe To Our Newsletter & Stay Updated
